Posts by Mourabit Halima

Chronic myeloid leukemia (CML) requires long-term treatment, emphasizing the importance of both efficacy and long-term safety and tolerability to achieve treatment goals, including treatment-free remission (TFR). Asciminib (ASC) is the first specific inhibitor targeting the ABL myristoyl pocket (STAMP) of BCR:ABL1, offering high specificity and minimal off-target effects. From June 13-16, 2024, the 29th Annual Meeting of the European Hematology Association (EHA) was held in Madrid, Spain. At the conference, an international multicenter phase III randomized controlled study, ASC4FIRST (NCT04971226), compared the efficacy and safety of ASC with standard first-line TKIs for newly diagnosed CML patients. The results demonstrated that ASC as a first-line treatment for newly diagnosed CML has superior efficacy, safety, and tolerability compared to current TKIs. We have invited Professor Bingcheng Liu from the Leukemia Treatment Center at the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences , to review this study.

Lymphoma, a common malignant tumor of the hematological system, has always been a focus of research for innovative and optimized treatment strategies. In recent years, with the rise of immunotherapy and targeted therapy, lymphoma treatment strategies are undergoing revolutionary changes. The 29th Annual Meeting of the European Hematology Association (EHA) was grandly held from June 13-16, 2024, in Madrid, Spain. With the rapid development of hematology, Chinese research teams also showcased many innovative treatment plans and clinical research results at this year's EHA conference. At this meeting, Professor Haiwen Huang from The First Affiliated Hospital of Soochow University announced the results of a study on zanubrutinib combined with rituximab and chemotherapy (ZR-chemo) for the treatment of newly diagnosed mantle cell lymphoma. "Oncology Frontier - Hematology Frontier" invited Professor Haiwen Huang to share and interpret the findings of this study.

The 29th Annual Meeting of the European Hematology Association (EHA) was held from June 13-16, 2024, in Madrid, Spain. As the largest international event in the field of hematology in Europe, this conference attracts numerous renowned experts and scholars from around the world to share and discuss innovative concepts, the latest scientific research, and clinical study results in hematology. To gain a deeper understanding of the latest research in Chronic Myeloid Leukemia (CML), "Oncology Frontier - Hematology Frontier" has invited Professor Huanling Zhu from West China Hospital of Sichuan University, to provide an in-depth interpretation.

The 29th Annual Meeting of the European Hematology Association (EHA) was held from June 13 to 16, 2024, in Madrid, Spain. This conference, the largest international event in the field of hematology in Europe, attracts numerous renowned experts and scholars each year to share and discuss innovative ideas, the latest scientific research, and clinical findings in hematology. At this year's conference, the research team led by Professor Wenming Chen from Beijing Chao-Yang Hospital , Capital Medical University presented their findings in an oral presentation (S209) on the Phase II study of all-human BCMA-targeted CAR-T therapy for relapsed/refractory multiple myeloma (RRMM). To gain deeper insights into the latest research in the RRMM field, Oncology Frontier - Hematology Frontier invited Professor Wenming Chen for an in-depth discussion.